MedTrace Logo

A Study of TAVO101 in Atopic Dermatitis Patients

NCT06176040 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-11-18

No results posted yet for this study

Summary

This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.

Conditions

Interventions

DRUG

TAVO101

TAVO101 IV Infusion.

Sponsors & Collaborators

  • Tavotek Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Penelope Montgomery, MD · Optimal Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-03-15
Completion
2025-06-15

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06176040 on ClinicalTrials.gov